- Home
- CFR vs ROIV Comparison
CFR vs ROIV Comparison
Compare CFR & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFR
- ROIV
- Stock Information
- Founded
- CFR 1868
- ROIV 2014
- Country
- CFR United States
- ROIV United Kingdom
- Employees
- CFR N/A
- ROIV N/A
- Industry
- CFR Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- CFR Finance
- ROIV Health Care
- Exchange
- CFR Nasdaq
- ROIV Nasdaq
- Market Cap
- CFR 7.9B
- ROIV 8.4B
- IPO Year
- CFR N/A
- ROIV N/A
- Fundamental
- Price
- CFR $130.44
- ROIV $10.76
- Analyst Decision
- CFR Hold
- ROIV Buy
- Analyst Count
- CFR 15
- ROIV 4
- Target Price
- CFR $133.13
- ROIV $17.50
- AVG Volume (30 Days)
- CFR 402.1K
- ROIV 5.9M
- Earning Date
- CFR 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- CFR 3.06%
- ROIV N/A
- EPS Growth
- CFR 7.71
- ROIV N/A
- EPS
- CFR 9.11
- ROIV N/A
- Revenue
- CFR $2,038,108,000.00
- ROIV $122,585,000.00
- Revenue This Year
- CFR $11.62
- ROIV N/A
- Revenue Next Year
- CFR $3.90
- ROIV N/A
- P/E Ratio
- CFR $14.34
- ROIV N/A
- Revenue Growth
- CFR 5.45
- ROIV 140.04
- 52 Week Low
- CFR $94.09
- ROIV $8.73
- 52 Week High
- CFR $147.64
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- CFR 67.96
- ROIV 49.33
- Support Level
- CFR $121.27
- ROIV $10.58
- Resistance Level
- CFR $131.82
- ROIV $11.77
- Average True Range (ATR)
- CFR 2.65
- ROIV 0.34
- MACD
- CFR 1.73
- ROIV -0.05
- Stochastic Oscillator
- CFR 92.39
- ROIV 15.13
About CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $50 billion in assets (as of 2024 year-end), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based approach to banking that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through branch openings. The bank's sweet spot is small to medium-size Texas-based commercial clients.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.